This manuscript describes the synthesis of a new series of 2-amino-6-(trifluoromethoxy)benzoxazole derivatives (1-5) and a benzothiazine derivative (6) structurally related to riluzole, the only neuroprotective drug currently approved for the treatment of the amyotrophic lateral sclerosis. Preliminary results indicate that the synthesized compounds, in particular benzamide derivatives 3 and 4, are able to antagonize voltage-dependent Na + channel currents, and therefore they could be exploited as new inhibitors of these channels. Moreover, all compounds possess low binding affinity for GABA and NMDA receptors.
Synthesis of new 2-amino-6-(trifluoromethoxy)benzoxazole derivatives, analogues of riluzole / M.L. Calabrò, R. Caputo, R. Ettari , G. Puia, F. Ravazzini, M. Zappalà, N. Micale. - In: MEDICINAL CHEMISTRY RESEARCH. - ISSN 1054-2523. - 22:12(2013), pp. 6089-6095. [10.1007/s00044-013-0594-4]
Synthesis of new 2-amino-6-(trifluoromethoxy)benzoxazole derivatives, analogues of riluzole
R. Ettari;
2013
Abstract
This manuscript describes the synthesis of a new series of 2-amino-6-(trifluoromethoxy)benzoxazole derivatives (1-5) and a benzothiazine derivative (6) structurally related to riluzole, the only neuroprotective drug currently approved for the treatment of the amyotrophic lateral sclerosis. Preliminary results indicate that the synthesized compounds, in particular benzamide derivatives 3 and 4, are able to antagonize voltage-dependent Na + channel currents, and therefore they could be exploited as new inhibitors of these channels. Moreover, all compounds possess low binding affinity for GABA and NMDA receptors.Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.